Abstract
Modifying the entry of pyruvate into mitochondria may provide a unique approach to treat metabolic disease. The pharmacology of a new class of insulin sensitizers directed against a newly identified mitochondrial target may treat many aspects of nonalcoholic steatohepatitis, including fibrosis. This commentary suggests treating nonalcoholic steatohepatitis through a newly identified mechanism consistent with pathophysiology. (Hepatology Communications 2017;1:193-197).
Original language | English |
---|---|
Pages (from-to) | 193-197 |
Number of pages | 5 |
Journal | Hepatology Communications |
Volume | 1 |
Issue number | 3 |
DOIs | |
State | Published - 2017 |